Email Updates

You are here

AVAC in the News

  • There was good news and bad news in terms of HIV vaccine and therapeutics research, with several vaccine trials pushing forward even as one came to a premature halt.

    March 13, 2020
    Antibody Related Research, HIV Vaccine
    MedPage Today
  • Esnart Sikazindu’s stint with AVAC as a Fellow in 2020 is a step towards becoming an HIV prevention research advocate.

    March 6, 2020
    General
    Zambia Daily Mail
  • Before we begin the real story, a little bit of fiction. There is a cluster of houses of complex architecture. Unfortunately, they are in a neighbourhood teeming with the dangerous and cunning criminals. The houses are protec­ted by sophisticated security systems to fight off intruders. They have multiple layers of response mechanisms from the moment any intrusion is detected. They are engineered so that they can assess the threat perception and neutralize the intruder through a series of autonomous actions at different levels.

    February 22, 2020
    Outlook
  • HIV researchers in Kenya and around the world are regrouping to look for a way forward after a promising new vaccine failed a critical test.

    February 11, 2020
    Daily Nation
  • An HIV vaccine remains what South Africa and the world needs to prevent new HIV infections. This is in addition to a range of other HIV prevention tools that are available and in the pipeline. However, one of the HIV vaccine research studies, Uhambo (HVTN 702), has been stopped early because it was determined by an independent review body that it did not show a possibility to prevent HIV. This, for a moment, came as disappointing news; however, as South Africans we realise the search for a safe and effective HIV vaccine has to continue.

    February 6, 2020
    Daily Maverick
  • In another setback in the long quest to prevent HIV infection, a trial in South Africa has been shut down because an experimental vaccine was not working, federal health officials announced on Monday.

    February 4, 2020
    New York Times
  • A vaccine trial against HIV in South Africa has proven ineffective, prompting the National Institute of Allergy and Infectious Diseases to stop it. Scientists were cautiously optimistic about the trial, which involved 5,407 HIV-negative volunteers at 14 sites across South Africa.

    February 4, 2020
    Devex
  • One of the biggest HIV vaccine trials in the world, the HVTN 702 study, was stopped late on Monday because the vaccine had not been proven effective in preventing HIV. This is according to the United States National Institute of Allergy and Infectious Diseases (NIAID), who are one of the funders of the clinical trial.

    February 4, 2020
    Health-E News
  • The HIV vaccine that had moved furthest along in human testing does not work, and the $104 million trial in South Africa evaluating it has been stopped early.

    February 3, 2020
    Science
  • A clinical trial testing a promising HIV vaccine in more than 5,000 people in South Africa has been halted because it failed to show a benefit, US health officials said on Monday.

    February 3, 2020
    Reuters

Pages